Back to News
investment

Why This $14 Million Bet on Adtalem Global Stock Could Signal a Healthcare Education Pivot

newsfeedback@fool.com (Jonathan Ponciano)
Loading...
3 min read
0 likes
⚡ Quantum Brief
First Sabrepoint Capital Management LP acquired 135,000 shares of Adtalem Global Education for $13.97 million on February 13, 2026, marking a new 5.39% position in its portfolio. Adtalem, a workforce-focused education provider, offers healthcare and professional training through Chamberlain and Walden Universities, reporting $1.89 billion in revenue and $253.25 million in net income over the past year. The stock trades at $92.92, down 11.5% annually but with strong fundamentals: 12.4% revenue growth, 34.3% EPS increase, and 6.3% enrollment growth for 10 consecutive quarters. Adtalem raised full-year EPS guidance to $7.80–$8.00, with $368 million in free cash flow and a $750 million buyback authorization, signaling confidence in long-term growth. The investment reflects a bet on healthcare education demand, as Walden’s 27% revenue surge and 30.8% EBITDA margins highlight Adtalem’s resilience amid workforce shortages.
AI Audio Summary
0:00 / 0:00
Click to play
Gemini_Generated_Image_5thz005thz005thz.png
Quantum News · Media Library

This education provider delivers healthcare and professional training through campus and online programs for workforce-focused students.On February 13, 2026, First Sabrepoint Capital Management LP disclosed a new position in Adtalem Global Education (ATGE +2.67%), acquiring 135,000 shares in an estimated $13.97 million trade.What happenedAccording to a SEC filing dated February 13, 2026, First Sabrepoint Capital Management LP initiated a new position in Adtalem Global Education (ATGE +2.67%), acquiring 135,000 shares. The estimated transaction value was $13.97 million.What else to knowThis is a new position, now representing 5.39% of FIRST Sabrepoint Capital Management LP’s 13F reportable AUMTop holdings after the filing:NYSE: TPB: $43.36 million (17.8% of AUM)NASDAQ: FCFS: $31.08 million (12.8% of AUM)NASDAQ: LAUR: $16.84 million (6.9% of AUM)NASDAQ: CVCO: $15.95 million (6.6% of AUM)NYSE: ATGE: $13.97 million (5.7% of AUM)As of February 12, 2026, shares of Adtalem Global Education were priced at $92.92, down 11.5% over the past year and underperforming the S&P 500 by 24.41 percentage points.Company overviewMetricValueRevenue (TTM)$1.89 billionNet income (TTM)$253.25 millionPrice (as of market close 2/12/26)$92.92One-year price change(11.50%)Company snapshotAdtalem Global Education offers degree and non-degree programs in nursing, health professions, medical, veterinary, and online education through Chamberlain University, Walden University, and several medical/veterinary schools.The company generates revenue primarily from tuition and related educational services, leveraging both campus-based and online delivery models.It serves students seeking professional and graduate education in healthcare, public service, and related fields, with a focus on workforce-aligned credentials.Adtalem Global Education Inc. is a leading provider of workforce-oriented postsecondary education, operating across healthcare and professional training segments. The company combines in-person and online learning platforms to address the evolving needs of students and employers. Its diversified academic offerings and focus on high-demand fields position it as a key player in the education and training services industry.What this transaction means for investorsCapital is shifting toward businesses with durable enrollment growth and expanding margins, and this move reflects that shift. Adtalem recently posted $503.4 million in quarterly revenue, up 12.4% year over year, alongside adjusted EPS of $2.43, up 34.3%. Meanwhile, enrollment climbed 6.3% to 97,010 students, marking a 10th consecutive quarter of growth.The fund’s new $13.97 million stake now accounts for 5.39% of assets, placing it alongside concentrated positions in consumer and education names like TPB and LAUR. That concentration suggests conviction, not a flyer.Adtalem also raised full-year adjusted EPS guidance to $7.80 to $8.00 and ended the quarter with net leverage at just 0.9x. Free cash flow over the trailing twelve months reached $368.0 million, reinforcing the balance sheet flexibility behind its $750 million buyback authorization.Long-term investors should focus on operating momentum. Walden revenue surged 27.0% year over year, and adjusted EBITDA margins expanded to 30.8% companywide. If healthcare workforce shortages persist, scale and profitability could prove far more valuable than recent share price underperformance suggests.About the AuthorJonathan Ponciano is a contributing stock market analyst at The Motley Fool. He has nearly a decade of experience as a financial journalist, most recently as an editor and senior reporter at Forbes focused on markets, technology, and entrepreneurship. Jonathan has also written for Investopedia and the Los Angeles Business Journal. He holds a dual B.A. in Business Journalism and Economics from the University of North Carolina at Chapel Hill and an M.B.A. from Columbia Business School. A North Carolina native now based in New York City, Jonathan has also lived in Mexico City and Los Angeles.CMFjonponcStocks MentionedAdtalem Global EducationNYSE: ATGE$95.40 (+2.67%) $+2.48*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Read Original

Source Information

Source: The Motley Fool

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.